UK cancer charities merge; will have L130M R&D spend
Two leading UK charities, the Cancer Research Campaign and ImperialCancer Research, are to merge to become Cancer Research UK, combining their complementary strengths to push through new and effective treatments and creating the largest independent cancer research organization in the world.
The merger will take effect early-February 2002 and the new organization will have a team of 3,000 researchers and doctors, with an annual scientific spend of L130 million ($196.6 million). However, in order to make more money available for research, optimize efficiency and avoid duplication of roles, there will be a reduction of around 30 jobs from the charities' support and administration staff.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze